Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma

被引：43

作者：

Mohan, Meera ^{[1
]}

Chakraborty, Rajshekhar ^{[2
]}

Bal, Susan ^{[3
]}

Nellore, Anoma ^{[4
]}

Baljevic, Muhamed ^{[5
]}

D'Souza, Anita ^{[1
]}

Pappas, Peter G. ^{[4
]}

Berdeja, Jesus G. ^{[6
]}

Callander, Natalie ^{[7
]}

Costa, Luciano J. ^{[3
]}

机构：

[1] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA

[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Multiple Myeloma & Amyloidosis Program, New York, NY USA

[3] Univ Alabama Birmingham, Div Hematol & Med Oncol, Birmingham, AL 35294 USA

[4] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA

[5] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Univ Wisconsin, Dept Med, Div Hematol & Oncologye, Madison, WI USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 203卷 / 05期

关键词：

bispecific T-cell; chimeric antigen receptor T-cell; immunotherapy; infection; multiple myeloma; INTRAVENOUS IMMUNOGLOBULIN; CILTACABTAGENE AUTOLEUCEL; BCMA; COMPLICATIONS; 1ST-IN-HUMAN; PROPHYLAXIS; SURVIVAL; RISK;

D O I：

10.1111/bjh.18909

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T-cell exhaustion, cytokine-release syndrome and immune-effector cell-associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T-cell and bispecific antibody therapies in MM patients.

引用

页码：736 / 746

页数：11

共 62 条

[1] Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients [J].

Abid, Muhammad Bilal ;

Rubin, Micah ;

Ledeboer, Nathan ;

Szabo, Aniko ;

Longo, Walter ;

Mohan, Meera ;

Shah, Nirav N. ;

Fenske, Timothy S. ;

Abedin, Sameem ;

Runaas, Lyndsey ;

D'Souza, Anita ;

Chhabra, Saurabh ;

Dhakal, Binod ;

Hamadani, Mehdi .

CANCER CELL, 2022, 40 (04) :340-342

[2] Prevention and Treatment of Cancer-Related Infections, Version 2.2016 [J].

Baden, Lindsey Robert ;

Swaminathan, Sankar ;

Angarone, Michael ;

Blouin, Gayle ;

Camins, Bernard C. ;

Casper, Corey ;

Cooper, Brenda ;

Dubberke, Erik R. ;

Engemann, Ashley Morris ;

Freifeld, Alison G. ;

Greene, John N. ;

Ito, James I. ;

Kaul, Daniel R. ;

Lustberg, Mark E. ;

Montoya, Jose G. ;

Rolston, Ken ;

Satyanarayana, Gowri ;

Segal, Brahm ;

Seo, Susan K. ;

Shoham, Shmuel ;

Taplitz, Randy ;

Topal, Jeffrey ;

Wilson, John W. ;

Hoffmann, Karin G. ;

Smith, Courtney .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (07) :882-913

[3] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study [J].

Bahlis, Nizar Jacques ;

Tomasson, Michael H. ;

Mohty, Mohamad ;

Niesvizky, Ruben ;

Nooka, Ajay K. ;

Manier, Salomon ;

Maisel, Christopher ;

Jethava, Yogesh ;

Martinez-Lopez, Joaquin ;

Prince, H. Miles ;

Arnulf, Bertrand ;

Rodriguez Otero, Paula ;

Koehne, Guenther ;

Touzeau, Cyrille ;

Raje, Noopur ;

Iida, Shinsuke ;

Raab, Marc-Steffen ;

Leip, Eric ;

Sullivan, Sharon ;

Conte, Umberto ;

Viqueira, Andrea ;

Lesokhin, Alexander M. .

BLOOD, 2022, 140

[4] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[5] Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients [J].

Blimark, Cecilie ;

Holmberg, Erik ;

Mellqvist, Ulf-Henrik ;

Landgren, Ola ;

Bjoekholm, Magnus ;

Hultcrantz, Malin ;

Kjellander, Christian ;

Turesson, Ingemar ;

Kristinsson, Sigurdur Y. .

HAEMATOLOGICA, 2015, 100 (01) :107-113

[6] Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications [J].

Blombery, Piers ;

Prince, H. Miles ;

Worth, Leon J. ;

Main, Jo ;

Yang, Melissa ;

Wood, Erica M. ;

Westerman, David A. .

ANNALS OF HEMATOLOGY, 2011, 90 (10) :1167-1172

[7] RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study [J].

Carlo-Stella, Carmelo ;

Mazza, Rita ;

Manier, Salomon ;

Facon, Thierry ;

Yoon, Sung-Soo ;

Koh, Youngil ;

Harrison, Simon J. ;

Er, Jeremy ;

Pinto, Antonio ;

Volzone, Francesco ;

Perrone, Giulia ;

Corradini, Paolo ;

Cazaubiel, Titouan ;

Hulin, Cyrille ;

Touzeau, Cyrille ;

Moreau, Philippe ;

Ocio, Enrique M. ;

Gaisan, Carmen Maria Montes ;

Popat, Rakesh ;

Leong, Sarah ;

Offner, Fritz ;

Otero, Paula Rodriguez ;

Alfonso-Pierola, Ana ;

Broeske, Ann-Marie E. ;

Dekhtiarenko, Iryna ;

Helms, Hans-Joachim ;

Belli, Sara ;

Rossmann, Eva ;

Fauti, Tanja ;

Eckmann, Jan ;

Moore, Tom ;

Schneider, Meike ;

Jacob, Wolfgang ;

Weisser, Martin ;

Hutchings, Martin ;

Riley, Caroline Hasselbalch .

BLOOD, 2022, 140

[8] RANDOMIZED TRIAL OF INTRAVENOUS IMMUNOGLOBULIN AS PROPHYLAXIS AGAINST INFECTION IN PLATEAU-PHASE MULTIPLE-MYELOMA [J].

CHAPEL, HM ;

LEE, M ;

HARGREAVES, R ;

PAMPHILON, DH ;

PRENTICE, AG .

LANCET, 1994, 343 (8905) :1059-1063

[9] Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody [J].

Chari, Ajai ;

Minnema, Monique C. ;

Berdeja, Jesus G. ;

Oriol, Albert ;

van de Donk, Niels W. C. J. ;

Rodriguez-Otero, Paula ;

Askari, Elham ;

Mateos, Maria-Victoria ;

Costa, Luciano J. ;

Caers, Jo ;

Verona, Raluca ;

Girgis, Suzette ;

Yang, Shiyi ;

Goldsmith, Rachel B. ;

Yao, Xiang ;

Pillarisetti, Kodandaram ;

Hilder, Brandi W. ;

Russell, Jeffery ;

Goldberg, Jenna D. ;

Krishnan, Amrita .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24) :2232-2244

[10] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma [J].

D'Souza, Anita ;

Shah, Nina ;

Rodriguez, Cesar ;

Voorhees, Peter M. ;

Weisel, Katja ;

Bueno, Orlando F. ;

Pothacamury, Rajvineeth K. ;

Freise, Kevin J. ;

Yue, Susan ;

Ross, Jeremy A. ;

Polepally, Akshanth R. ;

Talati, Chetasi ;

Lee, Shane ;

Jin, Ziyi ;

Buelow, Ben ;

Vij, Ravi ;

Kumar, Shaji .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) :3576-+

← 1 2 3 4 5 6 7 →